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A variety of treatments, including radiotherapy, endocrine treat-
ment, chemotherapy and bisphosphonates, are used for the
treatment of metastatic bone disease and evaluation of their
effects is important for both routine clinical practice and research.
The current methods used to assess response to these treatments
are qualitative and routinely include plain radiographs, radio-
nuclide bone scans and, in particular situations, computerized
tomography (CT).
The response assessment of bone metastases to therapy is
notoriously difficult, as the events in the healing process are slow
to evolve and quite subtle, with sclerosis of lytic lesions only
beginning to appear 3–6 months after the start of therapy
(Coleman, 1998). Confounding factors include the appearance of
sclerosis in a previously normal area on the radiograph; this may
indicate a new metastasis but equally may indicate a response,
representing an example of the healing flare phenomenon within a
lesion which was present at the start, but not destructive enough
to be radiologically visible (Galasko, 1994). The evaluation of
response in osteosclerotic lesions is even more difficult with
most patients with sclerotic metastases eventually classified as
either ‘no change’ (NC) to therapy or as unassessable; for these
patients, decisions about the efficacy of treatment are based on
symptomatic response or (when present) change in extraskeletal
disease.
All these pitfalls in radiological assessment of response are
reflected in the correlation of radiological response and the clinical
course of bone metastases. Complete (CR) and partial responses
(PR) in bone appear to be less frequent than in other tissues
(Coleman and Rubens, 1985), and the survival prospects for
patients with PR or NC are similar (Howell et al, 1988). In view of
the limitations of the current imaging methods, patients with
metastatic disease confined to the bone are frequently excluded
from many therapeutic trials and patients with widespread
metastatic disease (including bone) have changes in soft tissue or
visceral disease as their main response parameters.
While recognizing that the changes seen on serial radiographs
remain the ‘gold standard’ for evaluating response to therapy,
alternative methods are urgently needed. Biochemical markers of
bone turnover have shown some promise in the assessment of
response in bone to systemic anticancer therapy (Coleman et al,
1988), as have tumour marker measurements (Robertson et al,
1991). Additionally, new assays have recently been developed to
measure the cross-linking molecule at either the N-terminal part
(NTx) (Hanson, 1992) or the C-terminal (Bonde et al, 1995) part
(Crosslaps) of type I collagen, providing a simple, specific indica-
tion of the rate of bone resorption. We have previously shown that
these markers are significantly increased in patients with bone
metastases and that urine levels decrease in response to bisphos-
phonate treatment (Vinholes et al, 1996, 1997a, 1997b).
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Summary This study was designed to evaluate new bone resorption and tumour markers as possible alternatives to serial plain radiographs
for the assessment of response to treatment. Thirty-seven patients with newly diagnosed bone metastases from breast cancer, randomized
to receive oral pamidronate or placebo tablets in addition to anticancer treatment within the context of a multicentre EORTC trial, who were
both assessable for radiographic response in bone and had serum and urine samples collected for more than 1 month were studied. The
markers of bone metabolism measured included urinary calcium (uCa), hydroxyproline (hyp), the N-telopeptide cross-links of type I collagen
(NTx) and total alkaline phosphatase. The tumour markers measured were CA15-3 and cancer-associated serum antigen (CASA). Before
treatment, levels of Ntx, uCa and Hyp were elevated in 41%, 24% and 28% respectively, and CA15-3 and CASA increased in 69% and 50%.
For assessment of response and identification of progression, Ntx was the most useful bone marker. All markers behaved similarly in no
change (NC) and partial response (PR) patients. There was a significant difference (P ≤ 0.05) in Ntx levels (compared to baseline) at 1 and 4
months and in CA15-3/CASA at 4 months between patients with PR or NC and those with progressive disease (PD), and at 4 months
between those with time to progression (TP) > 7 and those with TP ≤ 7 months. The diagnostic efficiency (DE) for prediction of PD following
a > 50% increase in Ntx or CA15-3 was 78% and 62% respectively. An algorithm to predict response to therapy has been developed for future
prospective evaluation.
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Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UKThe aims of this study were to evaluate biochemical resorption
markers in breast cancer patients with bone metastases, and to
correlate the biochemical changes with clinical and tumour marker
response to treatment within a multicentre randomized trial. The
study was conducted in the context of an EORTC (European
Organization for Research and Treatment of Cancer) trial
(protocol 10924) designed to assess the effect of oral pamidronate,
in comparison to placebo, in reducing the rate of skeletal-related
events. The trial was stopped after 18 months because other trials
evaluating oral pamidronate were negative (unpublished data). In
addition, there were concerns about its absorption and gastro-
intestinal toxicity. These results will be reported elsewhere.
PATIENTS AND METHODS
Ninety patients with histologically proven breast cancer and radio-
logically confirmed newly diagnosed bone metastases identified
within the previous 6 weeks were randomized to receive oral
pamidronate 300 mg daily or identical placebo tablets in addition
to standard anticancer treatment as part of an EORTC multicentre,
randomized, double-blind trial. The choice of specific anticancer
treatment was left at the discretion of the patient’s treating physi-
cian and included radiotherapy, chemotherapy and endocrine
therapy.
Bone metastases were identified by radionuclide bone scan and
confirmed by plain radiographs. In patients with a solitary bone
metastasis, confirmation of bone involvement by CT or magnetic
resonance imaging (MRI) scan was necessary. Involvement of
other metastatic sites was allowed. No treatment with bisphospho-
nates within 6 months of randomization, or exposure to drugs
affecting bone metabolism, was allowed except for corticosteroids
taken for < 3 weeks duration. Other inclusion criteria included age
> 18 years; performance status 0–2; serum calcium < 2.8 mmol l–1
and life expectancy > 3 months. All patients gave written informed
consent.
Eight of the centres contributing patients to the trial took part in
this subprotocol exploring the use of alternative biochemical
markers of response. Thirty-seven patients with serial plain radio-
graphs, urine collections and serum samples were considered
evaluable for both radiographic and biochemical response and are
the subject of this report. However, one patient did not have serum
collected for tumour markers.
Response criteria
Radiographs of involved sites were performed at baseline, 4
months and at 3-monthly intervals thereafter. They were also
performed each time there was either a change in systemic therapy
or a skeletal event (fracture, radiotherapy to bone, hypercalcaemia,
radiological progression or spinal cord compression).
For this report, the effects of different treatments on both bone
and tumour markers were only evaluated for the first 7 months on
treatment as very few patients had samples collected beyond this
time. Only the response to first-line systemic treatment within
this trial is reported, as only a few patients were assessable for
response to subsequent treatments. Patients were also classified
according to the time to progression (TP) into two groups (TP of
³ 7 months and TP < 7 months).
Radiological response to treatment was evaluated according to
the UICC criteria (Hayward et al, 1977). All radiographs were
reviewed by two research fellows (J Vinholes and D Lacombe) in
conjunction with the investigators and local radiologists, and
without knowledge of the biochemical markers levels.
Subjective response to treatment was evaluated according to a
pain score, as previously described (Coleman, 1994). The pain
score was expressed as the percentage change from baseline.
Clinical response to treatment was defined as ³ 20% decrease in
the pain score compared to baseline reported on at least two
consecutive measurements. Patients with a decrease in pain of
< 20% were considered clinical non-responders.
Biochemical analysis
A fasting morning serum sample and a second voided urine
sample were collected from patients at baseline, 1 month after trial
entry and at 3-monthly intervals thereafter. Samples were also
collected in the event of a change in systemic therapy or skeletal
event. Serum measurements included full blood count, serum
calcium (sCa) corrected for albumin, total alkaline phosphatase
(tAP) creatinine and phosphate (PO4). Bone resorption markers
included urinary calcium (uCa), urinary hydroxyproline (hyp) and
urinary N-telopeptide peptide-bound cross-links (NTx) excretion.
Tumour markers measured included CA15-3 and CASA (cancer-
associated serum antigen). All bone resorption and tumour
markers were measured in batches in Sheffield. Samples were
stored at < –20°C and shipped on dry ice.
NTx was measured by an enzyme-linked immunoabsorbent
assay (ELISA) which uses a horseradish peroxidase labelled
monoclonal antibody that recognizes an epitope in the N-telopep-
tide cross-linking domain of type I collagen (OsteomarkTM,
Ostex®, Inc, Seattle, WA, USA). The detection limit was 20 nmol
BCE (bone collagen equivalent). The intra-assay and inter-assay
variability were 8% and 11% respectively. uCa was measured by a
colorimetric assay, and hyp by a colorimetric assay with dimethyl-
aminobenzaldehyde after acid hydrolysis and chloramine
T oxidation. All the urinary markers were expressed as a ratio to
creatinine excretion in the urine, measured using an automated
chemistry analyser by the kinetic Jaffe method.
To establish a control group for the bone resorption markers, we
had previously enrolled 40 healthy volunteers who were not taking
any medication with affects on bone metabolism (Vinholes et al,
1997a).
Statistical methods
As all markers showed a skewed distribution, data were logarith-
mically transformed and expressed as the geometric mean ± 2
standard deviation (s.d.). The baseline marker values of patients
were expressed as the geometric mean with 95% confidence inter-
vals. To compare patients with controls, we used the unpaired 
t-test after log transformation of the data and considered P < 0.05
as significant.
The response of each marker to treatment was expressed as the
percentage change from baseline and, as these data were also not
normally distributed, they were expressed as the geometric mean ±
standard error of the mean. The paired t-test with Bonferroni
correction was used to compare the percentage change for marker
values at each time-point with the baseline value. For determining
both the correlation between markers at baseline and after therapy,
Pearson’s correlation method was used. To compare changes in
pain within and between the groups, we used the Wilcoxon signed-
ranks test and the Mann–Whitney test respectively.
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identifying the response demonstrated by serial plain radiographs
was calculated. The positive predictive value is the proportion of
patients with positive test results who are correctly diagnosed radi-
ologically. The negative predictive value is the proportion of
patients with negative test results who are correctly diagnosed
radiologically. Diagnostic efficiency (DE) is the number of
patients with the correct diagnosis (true positive plus true nega-
tive) divided by the total number of patients. We calculated the
predictive values and DE of a decrease in bone turnover markers
and tumour markers of 10%, 20%, 30%, 40% and 50% from base-
line at 1 month to predict for a partial response and/or no change at
4 months. We also calculated the predictive values and diagnostic
efficiency of an increase in markers of 10%, 20%, 30%, 40% and
50% at 1 month to predict for progression at 4 months.
In an attempt to produce an algorithm to predict response, a
preliminary analysis of changes in various possible combinations
of markers and clinical response was performed. The cut-off value
for an individual marker was based on the least clinically signifi-
cant change – for Ntx this was 30% reduction (Blumsohn et al,
1994), 10% for both CA15-3 (Robertson et al, 1991) and alkaline
phosphatase (Coleman et al, 1988) and 20% for the pain score
(Vinholes et al, 1996, 1997b) – and the highest DE observed for
each parameter. These cut-off values are summarized in Table 1.
In each patient, the score for each variable was combined.
Progressive disease was considered as any positive value obtained,
and NC/PR as any negative value obtained or zero. These combi-
nations were then compared with the radiological response and
time to progression to determine whether they were of any predic-
tive value.
RESULTS
The baseline characteristics of the patients are shown in Table 2.
No significant differences were observed between these groups,
except for the type of anticancer treatment received. Fourteen
patients in the pamidronate arm received hormone therapy (seven
tamoxifen, four megestrol acetate, two aminogluthetimide and one
goserelin) and only three chemotherapy (anthracycline-based
regimen). In the placebo arm, ten received endocrine treatment
(six tamoxifen, three megestrol acetate and one ovarian ablation)
and ten chemotherapy (eight anthracycline-based regimens, one
methotrexate-based regimen and one vinorelbine).
Pre-treatment markers
Baseline values of the markers are shown in Table 3, except for
tAP which, because it was measured at each centre by various
methods, could not be reliably compared to our control patients.
Patients in both groups had similar levels and are reported
together. There was no difference in the levels of baseline markers
with regard to menopausal status or between patients on
chemotherapy or endocrine treatment.
The mean values of NTx and hyp were 50% and 25% higher,
respectively, in patients than in controls, while uCa was lower in
patients than in controls. CA15-3 and CASA were 36% and 11%
higher in patients than in controls respectively. In these patients
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Table 1 Scores assigned to changes in biochemical markers, tumour
markers and pain response for use in an algorithm to predict objective
radiological response to treatment
–1 0 +1
NTx ³ 30% fall < 30% fall or < 30 rise ³ 30% rise
CA15-3 ³ 10% fall < 10% fall or < 10% rise ³ 10% rise
tAP ³ 10% fall < 10% fall or < 10% rise ³ 10% rise
Pain score ³ 20% fall < 20% fall and no rise > 0% rise
NTx = N-telopeptide cross-links; tAP = total alkaline phosphatase.
Table 2 Baseline characteristics of patients
Pamidronate Placebo
(n = 17) (n = 20)
Median age (range) 60 (35–76) 48 (38–70)
Post-menopausal 11 12
Bone only disease 14 16
Multiple bone metastases 14 17
Median time from diagnosis (months) 24 24
Previous adjuvant therapy 9 15
Systemic treatment
Chemotherapy 3 10
Endocrine therapy 14 10
Median pain score (range) 3 (0–7) 5.5 (0–9)
Table 3 Baseline bone resorption and tumour markers
Marker Units Controls Patients Patients with
increased value
(%)
NTx nmol BCE mmol–1 55 (25–120) 84 (66–107) 41
Hyp mmol mmol–1 24 (11–48) 30 (26–35) 24
uCa mmol mmol–1 0.33 (0.13–0.53) 0.27 (0.21–0.34) 28
CA15-3 U ml–1 35* 48 (32–71) 69
CASA U ml–1 6a 6.7 (4.4–10.1) 50
aUpper limit of reference range. NTx = N-telopeptide cross-links; Hyp = hydroxyproline; uCa = urinary calcium;
CASA = cancer-associated serum antigen.with early metastatic bone disease, tumour marker levels were
more likely to be elevated than the bone resorption markers.
CA15-3 and CASA levels correlated with one another but not
with the bone resorption markers, even when patients with sites of
disease other than bone were excluded from the correlation. NTx
correlated with hyp, but only partially with uCa. tAP correlated
with NTx and hyp (Table 4).
Assessment of response at 4 months
There was a significant difference in mean NTx levels between
progressive disease (PD) patients versus NC or PR patients at 1
(P ≤ 0.05) and 4 months (P ≤ 0.01). Hydroxyproline only showed a
difference between these groups at 4 months, while uCa could not
differentiate between them (Figure 1). There was also a significant
difference in the CA15-3 levels between PD patients versus NC or
PR patients at 4 months (P ≤ 0.05), but not at 1 month, and no
significant difference at either time point with CASA (P = 0.09).
Time to progression (TP) at 7 months
NTx was the only bone resorption marker able to discriminate
reliably after 1 and 4 months of treatment between patients
progressing within 7 months of commencing treatment (TP ≤ 7)
and those with TP of > 7 months (Figure 2A). There was no signif-
icant differences in uCa and hyp levels between these groups. Both
levels of CA15-3 and CASA were also significantly different in
the two groups (Figure 2B, C).
Predictive values
The DE of tAP was greatest at a 10% change, and for CA15-3 and
CASA with a 10–20% change. To predict response, the DE of NTx
and uCa was greatest with a 30% change, while to predict progres-
sion the DE with these markers was greatest with a 30–50% change
(Figure 3). When some of these cut-offs values were used to build an
algorithm, the best combination to predict response was NTx, tAP
and clinical (pain score) response, although other combinations and
even individual variables had similar results (Table 5). We also
calculated the predictive values of an increase in markers of 20%,
30% and 50% whenever it occurred to predict for progression. The
greatest DE of the resorption markers and CA15-3 was obtained
with an increase of 50%, as shown in Table 6.
Pain score
Five patients were pain-free without any analgesics at baseline and
remained pain-free during the trial. These patients could not be
included in this analysis. Four of them were in the PR/NC, and one
in the PD, group. We correlated changes in the pain score with
radiological changes at 4 months. PD patients had a significantly
worse pain score when compared to PR/NC patients at 1 and 4
months. Five patients were considered as pain responders at 4
months. Four of them were in the PR/NC group. Four other
patients were considered pain responders at 7 months, two were
PR/NC and two were in the PD group.
Bone resorption and tumour marker levels were compared in
clinical responders and non-responders. Only NTx showed a
significant difference in mean values between the two clinical
response groups; this was most marked after 4 months of treatment
(P ≤ 0.01) (Figure 4).
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Table 4 Correlations (r values) between bone resorption markers and
tumour markers at baseline
Marker Ntx Hyp uCa TAP CA15-3 CASA
NTx 1
Hyp 0.66a 1
uCa 0.45b 0.59b 1
tAP 0.57b 0.53b 0.37 1
CA15-3 0.32 0.26 0.19 0.22 1
CASA 0.23 0.19 0.13 0.12 0.52b 1
aP ≤ 0.01, b P ≤ 0.05. NTx = N-telepeptide cross-links; Hyp = hydroxyproline;
uCa = urinary calcium; CASA = cancer-associated serum antigen.
Table 5 Predictive values of changes in markers at 1 month for response to
treatment as determined at 4 months
Marker (s) PV + PV– DE
(%) (%) (%)
NTx (³ 30% fall) 95 41 69
CA15-3 (³ 10% fall) 82 41 61
tAP (³ 10% fall) 94 47 69
Pain score (³ 20% fall) 94 47 69
NTx + CA15-3 95 35 44
NTx + Pain score 95 53 56
tAP + Pain score 89 53 53
NTx + tAP 95 58 64
NTx + tAP + Pain score 95 70 72
NTx + CA15-3 + Pain score 95 53 58
NTx + tAP + CA15-3 100 53 56
NTx + tAP + CA15-3 + Pain score 100 58 61
PV + = positive predictive value; PV – = negative predictive value; DE =
diagnostic efficiency. NTx = N-telopeptide cross-links; tAP = total alkaline
phosphatase.
Table 6 Predictive value for PD of a 50% increase in markers or pain
whenever it occurs
PV+ PV– DE
(%) (%) (%)
NTx 81 76 78
Hyp 57 62 59
uCa 62 25 46
tAP 94 33 59
CA15-3 75 52 62
CASA 50 52 51
Pain score 100 6 42
PV+ = positive predictive value; PV– = negative predictive value;
DE = diagnostic efficiency. NTx = N-telopeptide cross-links;
Hyp = hydroxyproline; uCa = urinary calcium; tAP = total alkaline
phosphatase; CASA = cancer-associated serum antigen.Assessment of bone response 225
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Figure 1 Changes from baseline in bone and tumour markers by response category assigned at assessment of response after 4 months treatment. PR, n = 8;
NC, n = 12; PD, n = 17. Significance levels between groups are shown as *P ≤ 0.05, **P < 0.01. NTx = N-telopeptide; Hyp = hydroxyproline; uCa = urinary
calcium; tAP = total alkaline phosphatase; CASA = cancer-associated serum antigenInfluence of underlying treatment
The choice of systemic anticancer treatment had no significant
effect on the changes seen in bone resorption markers including
NTx, but the changes seen in tumour markers were larger after
chemotherapy than endocrine therapy. Patients receiving oral
pamidronate had a significant reduction in NTx from baseline
(P < 0.001) compared with no overall change in NTx in the
placebo group indicating that, despite the rather poor tolerability
and low absorption of this bisphosphonate, sufficient quantities
were reaching the bone surface to influence bone metabolism.
DISCUSSION
Bone is the only site of metastatic disease that has separate criteria
for evaluation of response to treatment, based on bone repair and
destruction rather than changes in tumour volume (Hayward et al,
1977). Assessing response to treatment in bone is more difficult
than evaluation of disease in viscera and soft tissues where direct
tumour measurements can usually be taken.
Because bone metastases inevitably perturb the function of
normal bone cells, biochemical markers of bone resorption have
been studied as possible alternative response criteria. We have
shown that changes in NTx after 1–4 months of either endocrine
treatment or chemotherapy reflect with reasonable accuracy the
disease process as indicated by subsequent changes in plain
radiographs. NTx was the only bone resorption marker either to
correlate with radiological response at 4 and 7 months or to show a
difference between pain responders and non-responders. NTx was
also the bone resorption marker with the highest diagnostic
efficiency to detect PD whenever it occurred; PD patients showed
progressively higher values of NTx.
From our results we have proposed an algorithm based on the
changes in NTx, CA15-3 and clinical response seen after only
1 month of treatment in order to predict eventual radiographic
(objective) response. The algorithm was able to predict radiolog-
ical response and time to progression correctly in 70% of patients.
Prospective validation in a larger study should be attempted.
The changes seen in this study in collagen cross-link excretion
are similar to those of a preliminary report on the effects of
endocrine therapy (tamoxifen or megestrol acetate) in patients
with bone metastases from breast cancer on the urinary excretion
of the collagen cross-link deoxypyridioline (Dpd) measured by
high performance liquid chromatography (Downey et al, 1994).
After treatment, cross-links increased in patients with PD
(P < 0.05), but remained unchanged or decreased in patients with
stable disease or partial response. In another study, Blomqvist et al
(1996) monitored the serum C-telopeptide of type 1 collagen
(ICTP) and observed increasing levels of ICTP in PD patients,
although a few patients with increasing ICTP subsequently
showed a PR/NC.
None of the bone resorption or tumour markers could distin-
guish between NC and PR patients. In a recent trial in breast
cancer, ICTP could also not distinguish between these two cate-
gories of response (Blomqvist et al, 1996). However, although the
radiographic changes may differ in these two response categories,
several studies have shown that the survival prospects in patients
showing either stable disease for > 6 months or a partial response
are very similar (Coleman and Rubens 1985, Howell et al, 1988).
Our data support the notion that, in fact, these categories are
similar in terms of both biochemical response and clinical
outcome.
There is only one preliminary report on the use of collagen
cross-link measurements following systemic therapy associated
with bisphosphonates (Lipton et al, 1995). In this trial, 51 patients
(49 breast cancer, two myeloma) with bone metastases were
treated with either pamidronate 90 mg intravenously monthly or
placebo in addition to standard systemic therapy. During the 6
months of the trial, NTx was the marker that showed the most
significant decrease (P = 0.0006), while there was a smaller
difference with deoxypyridinoline (P = 0.03) and no detectable
difference with pyridinoline.
UCa excretion was low at baseline, showed no correlation with
radiological response at 4 months or 7 months, and did not
strongly correlate with either NTx at baseline, or with hyp or NTx
after treatment. In addition, uCa was the resorption marker with
the least diagnostic efficiency to detect PD. This contradicts the
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Figure 2 Changes from baseline in NTx (top), CA15-3 (middle) and CASA
(bottom) according to time to progression (TP) of < 7 months or ³ 7 months.
TP of < 7 months, n = 20; TP of ³ 7 months, n = 13. Significance levels
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Figure 3 Diagnostic efficiency (DE) of changes at 1 month from baseline in bone resorption markers (A), tumour markers (B) and tAP (C) to predict objective
response at 4 monthsvalue of changes in uCa excretion reported in two previous studies
where there appeared to be a good correlation between response to
treatment and changes in uCa excretion (Campbell et al, 1987;
Coleman et al, 1988). However, both of these trials evaluated
patients with established progressive bone metastases in the
absence of bisphosphonates. In this study of patients with newly
diagnosed bone metastases, the disturbance in bone resorption was
less profound and half of the patients were receiving bisphospho-
nates which, through the stimulation of parathyroid hormone
production and consequent stimulation of renal tubular reabsorp-
tion of calcium, are known to suppress calcium excretion indepen-
dent of any skeletal effects of the treatment (Vinholes et al,
1997a).
Of the two tumour markers assessed, only CA15-3 showed a
correlation with radiological response at 4 months. There was no
correlation between tumour and bone resorption markers
suggesting they are reflecting different aspects of the disease
process and are probably complementary. The effects of
chemotherapy on tumour markers were more pronounced than the
effects of endocrine treatment, possibly suggesting greater anti-
tumour efficacy of chemotherapy in this sample of patients.
In conclusion, CA15-3 is the most sensitive marker to detect
newly diagnosed bone metastases and NTx the most useful resorp-
tion marker to assess response to treatment. Rising levels of NTx
and tumour markers generally indicate progression. NTx is a
sensitive resorption marker to detect the biochemical effects of
oral pamidronate. NTx was the only marker that correlated with
subjective response. We hope to test the algorithm to predict
response in bone to treatment and time to progression in a large
prospective study.
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Figure 4 Changes in NTx in pain responders (Resp, n = 9) and non-
responders (NResp, n = 21)